Home » Newsletters » BioWorld Science

BioWorld Science

April 20, 2018

View Archived Issues

AzurRx BioPharma's AZ-1103 safe and biologically active in preclinical model

Pfizer enrolling patients in phase III trial of glasdegib for the treatment of AML

Merck KGaA presents potent and selective ATM kinase inhibitor M-3541

FDA clears IND application for phase I/II study of OBI-3424

KB-103 receives orphan medicinal product designation in Europe

Shire and Takeda in discussions after Shire rejects three Takeda proposals for company

Pfizer's novel ADC CD123-CPI has broad potential for treating acute myeloid leukemia

FDA grants orphan drug designation for Oraxol for the treatment of angiosarcoma

Argos Therapeutics discontinues ADAPT study based on interim analysis results

FDA grants fast track designation for balixafortide plus eribulin for metastatic breast cancer

Phase II E4 Relief study of Donesta achieves primary objective

ApolloBio obtains license to Toca 511/Toca FC for greater China region

CD163, VCAM-1 identified as markers of liver injury in autoimmune hepatitis

Goofice tablet launched in Japan

Otsuka launches Rexulti in Japan

First-in-human study of FS-118 in advanced solid tumors enrolling subjects

FDA accepts Veloxis' sNDA for Envarsus XR

ADC Therapeutics presents potent antitumoral compounds in xenograft models

Johnson & Johnson reviews progress of first quarter 2018

FDA advisory committee recommends approval of Epidiolex for LGS and Dravet syndrome

Novel genetically altered broadly neutralizing antibodies protect monkeys from SHIV

EMA committee hands down negative opinion for masitinib in ALS

Relay Therapeutics and collaborator patent PTP-2C inhibitors

Plexxikon divulges novel IDO1 and/or TDO inhibitors

Vertex Pharmaceuticals identifies new PAR-2 antagonists

Medshine Discovery patents MAPK 14 inhibitors

Mission Therapeutics presents novel USP30 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...